Alexion Pharmaceuticals (ALXN) PT Lowered to $190 at Credit Suisse, Following Earnings
Tweet
Share
E-mail
Get Alerts ALXN Hot Sheet
Price: $167.65 --0%
Rating Summary:
11 Buy, 26 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 4 | New: 66
Rating Summary:
11 Buy, 26 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 4 | New: 66
Trade Now!
Join SI Premium – FREE
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Credit Suisse analyst Martin Auster lowered the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $190.00 (from $194.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: JPMorgan Upgrades GCM Grosvenor Inc. (GCMG) to Overweight
- Lloyds Banking Group Plc. (LLOY:LN) (LYG) PT Raised to GBP47 at UBS
- UPDATE: Morgan Stanley Upgrades Skechers USA (SKX) to Overweight
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Credit Suisse, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
